Lederfolin (Calcium Levofolinate)

Calcium Levofolinate is converted inside cells to the active reduced folate form, 5‑methyltetrahydrofolate. This bypasses the blocked dihydrofolate reductase step, replenishing folate pools needed for DNA synthesis, thereby protecting healthy tissue from methotrexate and augmenting 5‑fluorouracil’s antimetabolite action.

The dose of Lederfolin is individualized and determined by the prescribing clinician based on the specific indication, patient weight, renal function, and concurrent chemotherapy regimen. Exact dosing instructions should be obtained from the treating physician.

The safety of Lederfolin during pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Lederfolin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Lederfolin (Calcium Levofolinate) provides a reduced folate form that can be administered intravenously, offering rapid plasma concentrations. Compared with oral folic acid, it bypasses intestinal absorption and is more effective for immediate rescue after high‑dose methotrexate. Its safety profile is similar to other injectable folate derivatives.

Lederfolin must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required for infusion.

Lederfolin is administered intravenously, typically as an infusion over a few minutes to several hours, depending on the clinical protocol. The exact infusion rate and timing relative to methotrexate or 5‑fluorouracil are determined by the treating oncologist.

Serious risks include severe allergic reactions such as anaphylaxis, persistent hypotension, acute renal impairment, and significant hepatic dysfunction. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Lederfolin is contraindicated in patients with known hypersensitivity to calcium levofolinate or any component of the formulation. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be avoided in pregnant women unless the therapeutic benefit outweighs potential risks.